Does DEMCIZUMAB Cause Malignant neoplasm progression? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Malignant neoplasm progression have been filed in association with DEMCIZUMAB. This represents 4.4% of all adverse event reports for DEMCIZUMAB.
6
Reports of Malignant neoplasm progression with DEMCIZUMAB
4.4%
of all DEMCIZUMAB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DEMCIZUMAB?
Of the 6 reports.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DEMCIZUMAB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does DEMCIZUMAB Cause?
Non-small cell lung cancer (18)
Disease progression (15)
Pancreatic carcinoma metastatic (12)
Drug ineffective (11)
Dehydration (10)
Off label use (10)
Pancytopenia (10)
Hypotension (8)
Metastases to central nervous system (8)
Metastases to liver (8)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DEMCIZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
DEMCIZUMAB vs DEMEROL
DEMCIZUMAB vs DENOSUMAB
DEMCIZUMAB vs DEOXYCHOLIC ACID
DEMCIZUMAB vs DEPAKINE CHRONO
DEMCIZUMAB vs DEPAKOTE